The Study Focused on Reducing Tobacco Smoke Exposure for Child.NCT01317628
Effects of Tobacco Smoke Exposure on Epigenetic Signatures and Immunotoxicological Reactions
A study testing Tobacco smoke reduction trial intervention program in people with The Study Focused on Reducing Tobacco Smoke Exposure for Child., run by National Taiwan University Hospital.
Trial summary
Researchers have noted that active smoke exposure was possibly related to epigenetic mechanism,and may further influence reactive immunotoxicological reaction on human beings. Some studies have been reported that smoking reduction would decrease the prevalence of respiratory symptoms and urinary cotinine level, but… Read more about this study
- Who is it for?
- Ages 12 to 16 yearsHealthy volunteers can take part
- Conditions the study is for
- The Study Focused on Reducing Tobacco Smoke Exposure for Child.
- What is being tested?
- Tobacco smoke reduction trial intervention program
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- Apr 2011to Jun 2011
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 16 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- age between 12 and 16 years old; (2) Child had active smoking habit; and (3) have prior history of smoking habit.
Who cannot join
- We will exclude children who do not fit in with the inclusion criteria.
About this study
Researchers have noted that active smoke exposure was possibly related to epigenetic mechanism,and may further influence reactive immunotoxicological reaction on human beings. Some studies have been reported that smoking reduction would decrease the prevalence of respiratory symptoms and urinary cotinine level, but the underlying epigenetic mechanism and the functional changes of immunotoxicological system were still unclear. We plan to examine the causal relationship between smoking reduction and alterations in epigenetic signatures/immunotoxicological reactions. Teenager Smoking Reduction Trial (TSRT) will be population-based trial among teenagers. Eligible teenagers will be recruited in Taipei City and urinary cotinine level will be used to monitor the exposure status of active smoking at baseline, 1-month and 3-month of the intervention process. We will assess the potential change in immunotoxicological markers, including Th1/Th2 cytokines and clinical immunological measurements, before and after the intervention program. Furthermore, whole-genome methylation and miRNA expression microarrays will be used to search candidate genes for teenager smoking exposure. We plan to develop a prediction model for immunotoxicological reaction by utilizing epigenetic signature data from microRNA expression and DNA methylation profiles based on machine learning methodologies. We will also establish a personalized epigenetic prediction model for allergy development and build the risk assessment platform for immunotoxicological reaction under tobacco smoke exposure. Finally, we will examine the causal relationship between epigenetic signatures and immunotoxicological reactions under an independent children's cohort.
Read the detailed description
Teenager Smoking Reduction Trial (TSRT)
- Study subjects TSRT is a solution-oriented trial aiming to evaluate the effectiveness of tobacco smoke reduction among teenagers. Eligible teenagers will fit the following criteria: (a) age between 12 and 16 years old; (b) have active smoke habits in past 6 months; (c) amount of smoke exceed 10 cigarettes per week. The subjects will be recruited from our previous database for schoolchildren. Telephone interview will be used to screen the eligibility for the teenagers. Recruitment will occur over 3-month period from 2011 April to June. The procedure for TSRT is showed in figure 2. In this plan, we will recruit at least 31 asthmatic children and 31 non-asthmatic children who have active smoke habits.
- Data collection
A baseline data and at the 1-month and 2-month follow-up visits, the primary caregiver provided data by personal interview on parents reports. The demographic information in questionnaires included age, gender, level of education.
Teenagers will report the frequency of cigarette smoking by using a structured questionnaire. The definition of tobacco smoke exposure including: (a) ''Do you currently smoke?''-yes/no; (b) ''When did you begin to smoke regularly?''; (c) Smokers were also asked for the number of cigarettes they smoked on an average day. Nicotine dependence will be examined by using structure questionnaires from Fagerstrom model.
We will contact eligible teenagers individually to get informed consent before data collection. The effects of our teenager smoking reduction intervention program will be assessed by primary outcomes such as cotinine/creatinine ratio (CCR) and the status of tobacco smoke exposure from questionnaire. No matter which group the participant belongs to, intervention and usual control group, the secondary outcomes in all participants will be tested as follows:
- Cytokines. We will test levels of interleukin 4, 5, 13 (IL-4, 5, 13), tumor necrosis factor-α (TNF-α), interferon-gamma (INF-γ) and toll-like receptors 2, 4, 9 (TLR-2, 4, 9).
- Immunotoxicological reaction. We will determine levels of exhaled nitric oxide (eNO), serum eosinophil cationic protein (ECP) and absolute eosinophil count (AEC).
- Oxidative stress markers. Levels of the markers 8-hydroxy-2-deoxyguanosine (8-OHdG), malondialdehyde (MDA) and F2-isoprostane (Iso-P) will be examined.
After first session is applied, all participants will be tested for primary outcomes and secondary outcomes at baseline, month 1 and month 3 of the intervention process. We can then compare the biomarkers before and after the intervention program.
- Being tested
- Tobacco smoke reduction trial intervention program
- Keywords
- tobacco smoke, intervention program
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tobacco smoke reduction trial intervention programBehavioural
Both the parents and children will receive 8 times intervention program weekly in first session. The telephone counseling will reduce the child's tobacco smoke exposure every weekly in second session. The interventionist and child jointly select behavioral goals for reducing tobacco smoke exposure for the child to work toward. The goals will be formalized as a written smoke exposure reduction plan for any of four specific behaviors, as relevant to that family: (a) smoking cessation for the child, (b) making the child's primary home smoke-free, (c) making non-home locations smoke-free.
| Study group | Role | What they receive |
|---|---|---|
| Lifestyle counseling | Other | Both the parents and children will receive 8 times intervention program weekly in first session. The telephone counseling will reduce the child's tobacco smoke exposure every weekly in second session. The interventionist and child jointly select behavioral goals for reducing tobacco smoke exposure for the child to work toward. The goals will be formalized as a written smoke exposure reduction plan for any of four specific behaviors, as relevant to that family: (a) smoking cessation for the child, (b) making the child's primary home smoke-free, (c) making non-home locations smoke-free. Receives: Behavioral: Tobacco smoke reduction trial intervention program |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline in cotinine level at 3 months
Cotinine was the major proximate metabolite of nicotine,has been widely used as a biomarker of tobacco exposure. We will detect the urinary cotinine for children who had active smoking habit.
Measured: 3 month
Change from Baseline in smoking status at 3 months
The smoking status for children will be measure by structure questionnaire.
Measured: 3 months
Secondary outcomes (4)
Change from Baseline in DNA methylation at 3 months
Measured: 3 months
Change from Baseline in immunological cytokine at 3 months
Measured: 3 months
Change from Baseline in miRNA expression at 3 months
Measured: 3 months
Change from Baseline in immunological function at 3 months
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Mar 2011 (estimated)
- Study startApr 2011
- Primary completionJun 2011
- Study completionJun 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for The Study Focused on Reducing Tobacco Smoke Exposure for Child.Studies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Yungling Lee, Ph.D, Principal investigator, National Taiwan University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01317628
- Sponsor's protocol ID
- 201009040R
- Status last verified
- Oct 2013
- First submitted
- 8 Mar 2011
- Last updated
- 29 Oct 2013
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Oct 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Tobacco Smoke Exposure on Epigenetic Signatures and Immunotoxicological Reactions
- ClinicalTrials.gov ID
- NCT01317628
- Acronym / sponsor ID
- 201009040R
- Keywords
- tobacco smoke, intervention program
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Study start
- Apr 2011
- Primary completion
- Jun 2011 (actual)
- Study completion
- Jun 2011 (actual)
- First posted
- 17 Mar 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Researchers have noted that active smoke exposure was possibly related to epigenetic mechanism,and may further influence reactive immunotoxicological reaction on human beings. Some studies have been reported that smoking reduction would decrease the prevalence of respiratory symptoms and urinary cotinine level, but the underlying epigenetic mechanism and the functional changes of immunotoxicological system were still unclear. We plan to examine the causal relationship between smoking reduction and alterations in epigenetic signatures/immunotoxicological reactions. Teenager Smoking Reduction Trial (TSRT) will be population-based trial among teenagers. Eligible teenagers will be recruited in Taipei City and urinary cotinine level will be used to monitor the exposure status of active smoking at baseline, 1-month and 3-month of the intervention process. We will assess the potential change in immunotoxicological markers, including Th1/Th2 cytokines and clinical immunological measurements, before and after the intervention program. Furthermore, whole-genome methylation and miRNA expression microarrays will be used to search candidate genes for teenager smoking exposure. We plan to develop a prediction model for immunotoxicological reaction by utilizing epigenetic signature data from microRNA expression and DNA methylation profiles based on machine learning methodologies. We will also establish a personalized epigenetic prediction model for allergy development and build the risk assessment platform for immunotoxicological reaction under tobacco smoke exposure. Finally, we will examine the causal relationship between epigenetic signatures and immunotoxicological reactions under an independent children's cohort.
Detailed description
Teenager Smoking Reduction Trial (TSRT)
- Study subjects TSRT is a solution-oriented trial aiming to evaluate the effectiveness of tobacco smoke reduction among teenagers. Eligible teenagers will fit the following criteria: (a) age between 12 and 16 years old; (b) have active smoke habits in past 6 months; (c) amount of smoke exceed 10 cigarettes per week. The subjects will be recruited from our previous database for schoolchildren. Telephone interview will be used to screen the eligibility for the teenagers. Recruitment will occur over 3-month period from 2011 April to June. The procedure for TSRT is showed in figure 2. In this plan, we will recruit at least 31 asthmatic children and 31 non-asthmatic children who have active smoke habits.
- Data collection
A baseline data and at the 1-month and 2-month follow-up visits, the primary caregiver provided data by personal interview on parents reports. The demographic information in questionnaires included age, gender, level of education.
Teenagers will report the frequency of cigarette smoking by using a structured questionnaire. The definition of tobacco smoke exposure including: (a) ''Do you currently smoke?''-yes/no; (b) ''When did you begin to smoke regularly?''; (c) Smokers were also asked for the number of cigarettes they smoked on an average day. Nicotine dependence will be examined by using structure questionnaires from Fagerstrom model.
We will contact eligible teenagers individually to get informed consent before data collection. The effects of our teenager smoking reduction intervention program will be assessed by primary outcomes such as cotinine/creatinine ratio (CCR) and the status of tobacco smoke exposure from questionnaire. No matter which group the participant belongs to, intervention and usual control group, the secondary outcomes in all participants will be tested as follows:
- Cytokines. We will test levels of interleukin 4, 5, 13 (IL-4, 5, 13), tumor necrosis factor-α (TNF-α), interferon-gamma (INF-γ) and toll-like receptors 2, 4, 9 (TLR-2, 4, 9).
- Immunotoxicological reaction. We will determine levels of exhaled nitric oxide (eNO), serum eosinophil cationic protein (ECP) and absolute eosinophil count (AEC).
- Oxidative stress markers. Levels of the markers 8-hydroxy-2-deoxyguanosine (8-OHdG), malondialdehyde (MDA) and F2-isoprostane (Iso-P) will be examined.
After first session is applied, all participants will be tested for primary outcomes and secondary outcomes at baseline, month 1 and month 3 of the intervention process. We can then compare the biomarkers before and after the intervention program.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Lifestyle counseling | Other | Behavioral: Tobacco smoke reduction trial intervention programBoth the parents and children will receive 8 times intervention program weekly in first session. The telephone counseling will reduce the child's tobacco smoke exposure every weekly in second session. The interventionist and child jointly select behavioral goals for reducing tobacco smoke exposure for the child to work toward. The goals will be formalized as a written smoke exposure reduction plan for any of four specific behaviors, as relevant to that family: (a) smoking cessation for the child, (b) making the child's primary home smoke-free, (c) making non-home locations smoke-free. |
Who may qualify
- Ages
- 12 to 16 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (1 listed)
- age between 12 and 16 years old; (2) Child had active smoking habit; and (3) have prior history of smoking habit.
Key exclusion criteria (1 listed)
- We will exclude children who do not fit in with the inclusion criteria.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tobacco smoke reduction trial intervention programBoth the parents and children will receive 8 times intervention program weekly in first session. The telephone counseling will reduce the child's tobacco smoke exposure every weekly in second session. The interventionist and child jointly select behavioral goals for reducing tobacco smoke exposure for the child to work toward. The goals will be formalized as a written smoke exposure reduction plan for any of four specific behaviors, as relevant to that family: (a) smoking cessation for the child, (b) making the child's primary home smoke-free, (c) making non-home locations smoke-free. | Behavioural | Lifestyle counseling |
Primary outcome
Change from Baseline in cotinine level at 3 months
Time frame: 3 month
Cotinine was the major proximate metabolite of nicotine,has been widely used as a biomarker of tobacco exposure. We will detect the urinary cotinine for children who had active smoking habit.
Change from Baseline in smoking status at 3 months
Time frame: 3 months
The smoking status for children will be measure by structure questionnaire.
4 secondary outcomes
Change from Baseline in DNA methylation at 3 months
Time frame: 3 months
Change from Baseline in immunological cytokine at 3 months
Time frame: 3 months
Change from Baseline in miRNA expression at 3 months
Time frame: 3 months
Change from Baseline in immunological function at 3 months
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Oct 2013.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yungling Lee, Ph.D principal investigator
National Taiwan University Hospital
Questions about this trial
What is this clinical trial studying?
A study testing Tobacco smoke reduction trial intervention program in people with The Study Focused on Reducing Tobacco Smoke Exposure for Child., run by National Taiwan University Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Oct 2013. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from Baseline in cotinine level at 3 months (time frame: 3 month). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Oct 2013.